Andrew Hopkins, Exscientia CEO

Ex­sci­en­tia ter­mi­nates Bay­er pact half a year ear­ly, col­lect­ing small por­tion of €240M promised

Bay­er and Ex­sci­en­tia are wind­ing down their three-year col­lab­o­ra­tion, leav­ing the big Ger­man phar­ma to take the AI-de­signed com­pounds born out of the pact fur­ther.

Lon­don-based Ex­sci­en­tia re­vealed in its Q2 up­date that the part­ners have “mu­tu­al­ly agreed to end” their col­lab­o­ra­tion, which kicked off in ear­ly 2020, af­ter re­cent­ly achiev­ing a drug dis­cov­ery mile­stone. In an SEC fil­ing, Ex­sci­en­tia said it ter­mi­nat­ed the pact on May 30, about six months ear­ly.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.